Refine by
Emergency Treatment Articles & Analysis
42 news found
Finerenone is marketed as KerendiaTM or, in some countries, as FirialtaTM, and approved for the treatment of chronic kidney disease associated with type 2 diabetes (T2D) in more than 70 countries worldwide. ...
ByBayer AG
Since 1987, the goal of the foundation has been to invigorate emerging companies, providing support to young entrepreneurs, who stand out in the country's innovation-rich startup environment. ...
With >1,000 original applicants, this is a tremendous accomplishment, reflecting the interest and believe of industry experts in mitochondria-based therapies and its potential to emerge as a novel treatment modality. The award comes with $25,000 in prize money. ...
“Advanced cancer patients who have progressed following prior therapies have significant treatment needs that might benefit from a targeted approach with an EZH2 inhibitor. ...
An improvement of 1 grade or more at any time was achieved by 40% of patients. The most common hematologic treatment-emergent adverse event (AE) of any grade was thrombocytopenia, which was reported in 55% (grade ≥3: 18%) of patients. ...
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
Treatment-related adverse events (AEs) were predominantly mild and resolved without sequalae. ...
Under this contract (number 75A50122C00082), awarded under the 2004 Project BioShield Act, Aktiv will supply emergency autoinjectors containing pralidoxime chloride (2-PAM) to the CHEMPACK program, targeting proposed indications related to organophosphate poisoning including nerve agents. ...
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. ...
Government to develop yet another one of the critically important emergency treatment products” said the company founder and CEO, Amir Genosar. ...
However, due to its short half-life, buspirone is prescribed to be taken several times a day for management of anxiety, which can be challenging for patients and may lead to sub-optimal treatment outcomes. CTx-2103 will be designed as a once-daily, multi-dose tablet, which the Company believes will offer clear differentiation and compelling advantages over currently available ...
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have failed initial ...
These include patients with clear cell renal cell carcinoma (ccRCC), KRAS wild-type colorectal cancer (KRASwt CRC) and EGFR-mutant non-small cell lung cancer (EGFRmut NSCLC). Secondary endpoints include treatment-emergent adverse events, serious adverse events, PK, PD, and immunogenicity. ...
Food and Drug Administration (FDA) has granted orphan drug designation to XMT-2056, the company’s lead Immunosynthen STING-agonist ADC, for the treatment of gastric cancer. According to the American Cancer Society, gastric cancer (also referred to as stomach cancer) accounts for approximately 1.5 percent of all new cancers diagnosed in the United States each year, with an ...
SPRINTER (SG018; NCT04732949) was a global, randomised, placebo-controlled, double-blind clinical trial assessing the efficacy and safety of inhaled SNG001 for the treatment of adults hospitalised due to COVID-19 who required treatment withsupplemental oxygen. ...
Side effects were mild to moderate, with no serious or severe treatment-emergent adverse events, even without the dose-titration schedules commonly used by other therapeutics in this class. ...
Overall, 16 (4.1%) patients had at least one treatment-emergent adverse event that was considered possibly related/related to F-rhPSMA-7.3. ...
B244 was well tolerated with no SAEs; treatment related treatment emergent adverse events (TEAEs) were low in incidence, mild in severity, and transient. The most common treatment related event was application site pruritus (0.8%). “The favorable profile demonstrated in this study for safety and efficacy on both skin ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
“These results are an important step forward for the treatment of patients with metastatic hormone-sensitive prostate ...
ByBayer AG